Autopsy report · NCT02942758
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
Cause of deathFunding or business
“Due to financial reasons.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 11 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University Hospital Regensburg
- Sponsor type
- University, hospital or other
- Conditions
- Acute Myeloid Leukemia
- Interventions
- low-dose Azacitidine; Pioglitazone; ATRA; standard-dose AZA
- Participants
- 10
- Sites
- 1
- Countries
- Germany
Trials that died the same way
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
“Due to business reasons” - To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
“Due to lack of funds” - Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
“Due to lack of funding.” - Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension
“due to lack of finance” - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
“Due to administrative reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.